<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">URABE, FUMIHIKO</style></author><author><style face="normal" font="default" size="100%">KOBAYASHI, DAIGO</style></author><author><style face="normal" font="default" size="100%">IWATANI, KOSUKE</style></author><author><style face="normal" font="default" size="100%">IMAI, YU</style></author><author><style face="normal" font="default" size="100%">ONUMA, HAJIME</style></author><author><style face="normal" font="default" size="100%">AIKAWA, KOICHI</style></author><author><style face="normal" font="default" size="100%">YANAGISAWA, TAKAFUMI</style></author><author><style face="normal" font="default" size="100%">TASHIRO, KOJIRO</style></author><author><style face="normal" font="default" size="100%">SASAKI, HIROSHI</style></author><author><style face="normal" font="default" size="100%">MIKI, JUN</style></author><author><style face="normal" font="default" size="100%">MIKI, KENTA</style></author><author><style face="normal" font="default" size="100%">KIMURA, TAKAHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4611-4617</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.16655</style></doi><volume><style face="normal" font="default" size="100%">43</style></volume><issue><style face="normal" font="default" size="100%">10</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Clinical trials have shown that the efficacy of a reduced dose of cabazitaxel (20 mg/m2 every 3 weeks) was not inferior to that of the standard dose (25 mg/m2 every 3 weeks). However, the efficacy of even lower relative dose intensities, such as 20 mg/m2 every 4 weeks, have not been evaluated conclusively. The aim of this study was to investigate the efficacy and safety of a low relative dose intensity of cabazitaxel in patients with metastatic castration-resistant prostate cancer in the real world. Patients and Methods: We retrospectively analyzed 101 consecutive patients treated with cabazitaxel for docetaxel-refractory metastatic castration-resistant prostate cancer. The progression-free and overall survival after introduction of cabazitaxel and prostate-specific antigen response rate were assessed as oncological outcome measures. Results: The patients were divided into two groups (relative dose intensity &gt;60%, n=74 and ≤60%, n=27). Both progression-free and overall survivals were significantly better in the &gt;60% group than in the ≤60% group (median 5 and 2 months, p&lt;0.01, and 15 and 6 months, p&lt;0.01, respectively). In multivariate analyses, visceral metastasis and relative dose intensity ≤60% were prognostic factors for shorter progression-free and overall survivals (p=0.04, p&lt;0.01, respectively). The incidence of adverse events was not significantly different between groups. Conclusion: The cabazitaxel relative dose intensity ≤60% group had significantly shorter progression-free and overall survivals than the &gt;60% group, whereas the incidence of adverse events was not significantly different. The results suggested that reducing the relative dose intensity of cabazitaxel to ≤60% may not be recommended.</style></abstract></record></records></xml>